Epidemiological, clinical, and experimental reports have produced mixed conclusions about whether allergic asthma modifies risk for severe coronavirus disease. Allergic asthma is characterized by type 2 (T2) inflammation, mucus hypersecretion, and airway remodeling. The authors used an established house dust mite (HDM) respiratory exposure model to evaluate how preexisting allergic airway inflammation alters disease caused by three highly pathogenic coronaviruses: SARS-CoV-1, SARS-CoV-2, and MERS-CoV.
Respiratory HDM treatment induced canonical features consistent with allergic asthma in mice. Reported changes included goblet cell hyperplasia, increased mucin secretion, recruitment of eosinophils to the airways, polarization toward M2 macrophage phenotypes, and induction of IL-13. These features establish a T2-skewed airway environment prior to coronavirus infection in the experimental animals.
The study compared outcomes after infection with each of three coronaviruses in mice with or without prior HDM-induced allergic airway inflammation. Multiple SARS-CoV-2 variants were tested, and separate mouse models were used for MERS-CoV and SARS-CoV-1. Endpoints reported in the source include viral titers, weight loss, lung immunopathology, cytokine and chemokine signatures, and survival/lethality.
Across multiple SARS-CoV-2 variants, mice pretreated with HDM exhibited improved outcomes compared with non-allergic controls. The HDM-treated animals had reduced viral titers, experienced less weight loss, showed diminished lung immunopathology, and had improved survival rates. These findings indicate that preexisting allergic airway inflammation in this model was protective against SARS-CoV-2 disease manifestations.
A similar protective pattern was observed in the MERS-CoV mouse model. HDM-treated mice had reduced lethality and lower viral burden after MERS-CoV infection. The allergic animals also displayed blunted cytokine storm signatures relative to controls, consistent with attenuated hyperinflammatory responses in this model.
In contrast to SARS-CoV-2 and MERS-CoV, allergic airway inflammation worsened disease caused by SARS-CoV-1. HDM-treated mice infected with SARS-CoV-1 developed fulminant alveolar inflammation, suffered severe weight loss, exhibited elevated pro-inflammatory cytokines and chemokines, and experienced increased mortality. These deleterious outcomes occurred despite a reported reduction in virus titer, indicating a host-driven immunopathologic process that exacerbated disease.
The source reports T2-associated airway changes after HDM exposure (goblet cell hyperplasia, mucin, eosinophilia, M2 macrophage polarization, IL-13 induction) that preceded infection. Following viral challenge, differential outcomes were associated with distinct patterns of viral burden and inflammatory responses: protection for SARS-CoV-2 and MERS-CoV correlated with lower viral titers and blunted inflammatory signatures, whereas SARS-CoV-1 pathogenesis was driven by heightened alveolar inflammation and elevated pro-inflammatory cytokines and chemokines despite reduced viral load. The article frames these as virus-specific host–pathogen interactions influenced by preexisting allergic status.
These mouse-model findings provide a unifying explanation for apparently conflicting epidemiological and mechanistic reports across coronavirus epidemics: host allergic status can be a key determinant of disease outcome, but its effect is virus specific. The data suggest that preexisting allergic airway inflammation may confer protection against some coronaviruses (SARS-CoV-2, MERS-CoV) while worsening disease with others (SARS-CoV-1). The authors highlight the importance of considering allergic status when interpreting clinical risk and when studying pathogenesis of emerging coronaviruses.
The source article lists competing interest statements and funding relationships for investigators and laboratories involved; these include prior or unrelated sponsored research agreements and consultancy roles with several vaccine and pharmaceutical companies. The preprint was posted on bioRxiv and is available under a CC-BY 4.0 International license. For full experimental detail, numerical results, and methods, readers should consult the original preprint PDF as reported in the source.
In this HDM-driven mouse model of allergic airway inflammation, preexisting T2-skewed airway changes produced divergent, virus-specific effects on pathogenic coronaviruses: protection for SARS-CoV-2 and MERS-CoV and exacerbated, fatal immunopathology for SARS-CoV-1. These findings underscore that host allergic status is an important variable that can shape coronavirus disease outcomes and should be considered in mechanistic studies and epidemiological analyses.